Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, Sharaf M, Coates LC, Siebert S (2023)
Publication Type: Journal article, Erratum
Publication year: 2023
Journal
Book Volume: 25
Journal Issue: 1
DOI: 10.1186/s13075-023-03158-9
Authors with CRIS profile
Involved external institutions
Janssen Global Services, LLC
United States (USA) (US)
Johnson & Johnson Services, Inc.
United States (USA) (US)
University of Oxford
United Kingdom (GB)
University of Glasgow
United Kingdom (GB)
United States (USA) (US)
Johnson & Johnson Services, Inc.
United States (USA) (US)
University of Oxford
United Kingdom (GB)
University of Glasgow
United Kingdom (GB)
How to cite
APA:
Schett, G., Chen, W., Gao, S., Chakravarty, S.D., Shawi, M., Lavie, F.,... Siebert, S. (2023). Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Research & Therapy, 25(1). https://doi.org/10.1186/s13075-023-03158-9
MLA:
Schett, Georg, et al. "Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study." Arthritis Research & Therapy 25.1 (2023).
BibTeX: Download